UNLABELLED: Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), an adaptor protein for inflammasome receptors, is essential for inducing caspase-1 activation and the consequent secretion of interleukin-1β (IL-1β), which is associated with local inflammation during liver ischemia/reperfusion injury (IRI). However, little is known about the mechanisms by which the ASC/caspase-1/IL-1β axis exerts its function in hepatic IRI. This study was designed to explore the functional roles and molecular mechanisms of ASC/caspase-1/IL-1β signaling in the regulation of inflammatory responses in vitro and in vivo. With a partial lobar liver warm ischemia (90 minutes) model, ASC-deficient and wild-type mice (C57BL/6) were sacrificed at 6 hours of reperfusion. Separate animal cohorts were treated with an anti-IL-1β antibody or control immunoglobulin G (10 mg/kg/day intraperitoneally). We found that ASC deficiency inhibited caspase-1/IL-1β signaling and led to protection against liver ischemia/reperfusion (IR) damage, local enhancement of antiapoptotic functions, and down-regulation of high mobility group box 1 (HMGB1)-mediated, toll-like receptor 4 (TLR4)-driven inflammation. Interestingly, the treatment of ASC-deficient mice with recombinant HMGB1 re-created liver IRI. Moreover, neutralization of IL-1β ameliorated the hepatocellular damage by inhibiting nuclear factor kappa B (NF-κB)/cyclooxygenase 2 signaling in IR-stressed livers. In parallel in vitro studies, the knockout of ASC in lipopolysaccharide-stimulated bone marrow-derived macrophages depressed HMGB1 activity via the p38 mitogen-activated protein kinase pathway and led to the inhibition of TLR4/NF-κB and ultimately the depression of proinflammatory cytokine programs. CONCLUSION: ASC-mediated caspase-1/IL-1β signaling promotes HMGB1 to produce a TLR4-dependent inflammatory phenotype and leads to hepatocellular injury. Hence, ASC/caspase-1/IL-1β signaling mediates the inflammatory response by triggering HMGB1 induction in hepatic IRI. Our findings provide a rationale for a novel therapeutic strategy for managing liver injury due to IR.
UNLABELLED: Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), an adaptor protein for inflammasome receptors, is essential for inducing caspase-1 activation and the consequent secretion of interleukin-1β (IL-1β), which is associated with local inflammation during liver ischemia/reperfusion injury (IRI). However, little is known about the mechanisms by which the ASC/caspase-1/IL-1β axis exerts its function in hepatic IRI. This study was designed to explore the functional roles and molecular mechanisms of ASC/caspase-1/IL-1β signaling in the regulation of inflammatory responses in vitro and in vivo. With a partial lobar liver warm ischemia (90 minutes) model, ASC-deficient and wild-type mice (C57BL/6) were sacrificed at 6 hours of reperfusion. Separate animal cohorts were treated with an anti-IL-1β antibody or control immunoglobulin G (10 mg/kg/day intraperitoneally). We found that ASC deficiency inhibited caspase-1/IL-1β signaling and led to protection against liver ischemia/reperfusion (IR) damage, local enhancement of antiapoptotic functions, and down-regulation of high mobility group box 1 (HMGB1)-mediated, toll-like receptor 4 (TLR4)-driven inflammation. Interestingly, the treatment of ASC-deficientmice with recombinant HMGB1 re-created liver IRI. Moreover, neutralization of IL-1β ameliorated the hepatocellular damage by inhibiting nuclear factor kappa B (NF-κB)/cyclooxygenase 2 signaling in IR-stressed livers. In parallel in vitro studies, the knockout of ASC in lipopolysaccharide-stimulated bone marrow-derived macrophages depressed HMGB1 activity via the p38 mitogen-activated protein kinase pathway and led to the inhibition of TLR4/NF-κB and ultimately the depression of proinflammatory cytokine programs. CONCLUSION:ASC-mediated caspase-1/IL-1β signaling promotes HMGB1 to produce a TLR4-dependent inflammatory phenotype and leads to hepatocellular injury. Hence, ASC/caspase-1/IL-1β signaling mediates the inflammatory response by triggering HMGB1 induction in hepatic IRI. Our findings provide a rationale for a novel therapeutic strategy for managing liver injury due to IR.
Authors: J Masumoto; S Taniguchi; K Ayukawa; H Sarvotham; T Kishino; N Niikawa; E Hidaka; T Katsuyama; T Higuchi; J Sagara Journal: J Biol Chem Date: 1999-11-26 Impact factor: 5.157
Authors: Xiu-Da Shen; Bibo Ke; Yuan Zhai; Farin Amersi; Feng Gao; Dean M Anselmo; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Transplantation Date: 2002-08-15 Impact factor: 4.939
Authors: Sanjeev Mariathasan; Kim Newton; Denise M Monack; Domagoj Vucic; Dorothy M French; Wyne P Lee; Meron Roose-Girma; Sharon Erickson; Vishva M Dixit Journal: Nature Date: 2004-06-09 Impact factor: 49.962
Authors: Takao Ohtsuka; Hoon Ryu; Yohji A Minamishima; Salvador Macip; Junji Sagara; Keiichi I Nakayama; Stuart A Aaronson; Sam W Lee Journal: Nat Cell Biol Date: 2004-01-18 Impact factor: 28.824
Authors: Huan Yang; Mahendar Ochani; Jianhua Li; Xiaoling Qiang; Mahira Tanovic; Helena E Harris; Srinivas M Susarla; Luis Ulloa; Hong Wang; Robert DiRaimo; Christopher J Czura; Haichao Wang; Jesse Roth; H Shaw Warren; Mitchell P Fink; Matthew J Fenton; Ulf Andersson; Kevin J Tracey Journal: Proc Natl Acad Sci U S A Date: 2003-12-26 Impact factor: 11.205
Authors: Changyong Li; Yuting Jin; Song Wei; Yishuang Sun; Longfeng Jiang; Qiang Zhu; Douglas G Farmer; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Bibo Ke Journal: Hepatology Date: 2019-06-21 Impact factor: 17.425
Authors: Miklós Palotai; Edina Kiss; Zsolt Bagosi; Miklós Jászberényi; Gábor Tóth; Györgyi Váradi; Gyula Telegdy Journal: Neurochem Res Date: 2013-12-13 Impact factor: 3.996
Authors: Shi Yue; Jianjun Zhu; Ming Zhang; Changyong Li; Xingliang Zhou; Min Zhou; Michael Ke; Ronald W Busuttil; Qi-Long Ying; Jerzy W Kupiec-Weglinski; Qiang Xia; Bibo Ke Journal: Hepatology Date: 2016-08-29 Impact factor: 17.425
Authors: Min Zhang; Kojiro Nakamura; Shoichi Kageyama; Akeem O Lawal; Ke Wei Gong; May Bhetraratana; Takehiro Fujii; Dawoud Sulaiman; Hirofumi Hirao; Subhashini Bolisetty; Jerzy W Kupiec-Weglinski; Jesus A Araujo Journal: JCI Insight Date: 2018-10-04